Memo - Magazine of European Medical Oncology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Prostate cancer special —part 2
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - February 1, 2024 Category: Cancer & Oncology Source Type: research

“Navigating the evolving landscape of cancer treatment: a triad of progress”
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - February 1, 2024 Category: Cancer & Oncology Source Type: research

Innovative therapeutic concepts for biliary tumors
SummaryIn recent years there have been significant changes in the treatment of bile duct carcinoma. Immunotherapy has been included in first-line treatment for about a  year now (IO + cisplatin/gemcitabine). Cholangiocarcinomas are genetically very heterogeneous and several new targets have been identified in recent years. These play an important role, especially in second-line treatment. This review aims to highlight the key milestones of current treatment w ith a focus on targeted therapy options. Especially, current data on therapeutic options such as FGFR‑2, NTRK, IDH‑1, BRAF, HER‑2 are reported. (Source: M...
Source: Memo - Magazine of European Medical Oncology - January 29, 2024 Category: Cancer & Oncology Source Type: research

Can artificial intelligence provide accurate and reliable answers to cancer patients ’ questions about cancer pain? Comparison of chatbots based on ESMO cancer pain guideline
ConclusionAll chatbots are insufficient to obtain accurate information for cancer patients, and the resources are quite inadequate in acquiring accurate information for cancer patients and their families, and they need further development. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - January 26, 2024 Category: Cancer & Oncology Source Type: research

Antibody –drug conjugates in ovarian cancer
SummaryOvarian cancer (OC) management presents a  challenging scenario in clinical practice due to its late diagnosis, high recurrence rate, and dismal 5‑year survival rate of 45%—especially in platinum-resistant cases. Antibody–drug conjugates (ADCs) are novel drugs that enable the selective delivery of potent cytotoxic agents directly to tumor cells, thereby maximizing treatment effectiveness while minimizing harm to healthy cells. Recent studies have shown promising results in this regard. Mirvetuximab soravtansine achieved remarkable results in the MIRASOL trial, suggesting it as a potential new standard of car...
Source: Memo - Magazine of European Medical Oncology - January 25, 2024 Category: Cancer & Oncology Source Type: research

Acute myeloid leukemia patient with active disseminated tuberculosis bridged to transplant with reduced 14-day venetoclax and azacitidine schedule
SummaryA  59-year-old female patient was diagnosed with acute myeloid leukemia and tuberculosis. As a further complication, she developed idiopathic bowel perforation. Her infectious and intestinal situation demanded shorter periods of neutropenia and did not permit a high-dose, curative therapy regimen. Moreover, simultaneous administration of venetoclax and antitubercular therapy with rifampicin causes CYP3A4 interactions and thereby higher levels of toxicity. She was treated with a shortened, 14-day therapy regimen with azacitidine and venetoclax as antileukemic treatment together with ethambuto l, pyrazinamide, iso...
Source: Memo - Magazine of European Medical Oncology - January 23, 2024 Category: Cancer & Oncology Source Type: research

(Neo)adjuvant approaches in lung cancer —paving the road to a cure
SummaryImmune checkpoint inhibitors (ICI) have revolutionized the treatment landscape of metastatic non-small-cell lung cancer (NSCLC). During the past few years the focus of research has shifted toward examining these therapies in patients with early-stage NSCLC to improve long-term overall survival and cure rates. As recurrence rates are high and the relapse pattern in patients with completely resected early-stage NSCLC is predominantly systemic, high expectations rest on the integration of ICI therapy in their treatment approach. A  large number of studies with adjuvant or neo-adjuvant ICI are ongoing. The first data f...
Source: Memo - Magazine of European Medical Oncology - January 19, 2024 Category: Cancer & Oncology Source Type: research

Evidence and emerging trends in local therapy for metastatic hormone-sensitive prostate cancer: a  narrative review
ConclusionRT in combination with systemic therapy remains the established first-line treatment for low-burden mHSPC, though the exact definition of low metastatic burden remains contentious. Precise assessment of metastatic burden is vital to identify patients who would derive the greatest benefit from RT. As treatment paradigms evolve, embracing multimodal approaches holds potential for optimizing outcomes in patients with mHSPC. Further research is needed to solidify the role of cRP as a  standard therapeutic approach and to refine treatment strategies for improved patient outcomes. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - January 16, 2024 Category: Cancer & Oncology Source Type: research

Pulmonary puzzles: salivary gland-type tumors of the lung and their metastatic equivalents
SummaryIn the last decade, the understanding of lung neoplasms, particularly rare salivary gland-type tumors (SGT), has deepened significantly. This review intends to spotlight the latest findings, particularly emphasizing the differentiation between primary and metastatic SGTs in the lung. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - January 11, 2024 Category: Cancer & Oncology Source Type: research

Transformation of epidermal growth factor receptor-mutated non-small cell lung cancer into small cell lung cancer —case report
We report the case of a woman with stage IV adenocarcinoma progressing and transforming into SCLC while being treated with Afatinib at our institution. This case also highligh ts the importance of rebiopsy in progressive patients receiving TKI for EGFR-mutated NSCLC. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - January 8, 2024 Category: Cancer & Oncology Source Type: research

Molecular typing —new targets and therapy options for upper GI carcinomas with a focus on adenocarcinomas of the esophagus, gastroesophageal junction, and stomach
SummaryThe biomarker developments in adenocarcinomas of the esophagus, gastroesophageal junction, and stomach are currently very exciting. Clinical trial data for Claudin 18.2 and FGFR2b are promising and EMA approvals are expected. Routine testing includes PD-L1, HER2, and MSI. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - January 5, 2024 Category: Cancer & Oncology Source Type: research

Metastasis-directed therapy: new standard or too early to change paradigm?
SummaryMetastasis-directed therapy (MDT) is an emerging treatment strategy for patients with oligometastatic prostate cancer (PCa), particularly for oligorecurrent disease. This review aims to summarize findings from several prospective trials in the setting of oligorecurrent PCa. We found that MDT is feasible, has high tolerability, and is effective in terms of local control of treated lesions and of deferring disease progression in well-selected patients. Selecting patients for MDT requires thoughtful consideration of factors such as the castration status, the number of detected metastases, and the imaging modality used ...
Source: Memo - Magazine of European Medical Oncology - December 29, 2023 Category: Cancer & Oncology Source Type: research

Upper-GI highlights from ASCO and ASCO-GI 2023 meetings: changing paradigm in treatment sequence
SummaryThe annual meeting of the American Society of Medical Oncology (ASCO) was held as usual in Chicago, while the meeting focused on gastrointestinal tumors, ASCO-GI, was held in San Francisco. In particular, ASCO-GI included many phase  III trials, the data of which have the potential to change the practice in the near future for tumors of the upper gastrointestinal tract (upper-GI), including tumors of the esophagus, gastroesophageal junction, stomach, and pancreas. Interestingly, ASCO and also the European Society for Medical O ncology (ESMO) offer the virtual plenary sessions under the motto “Today’s Science Ca...
Source: Memo - Magazine of European Medical Oncology - December 29, 2023 Category: Cancer & Oncology Source Type: research

Total neoadjuvant therapy for each locally advanced rectal cancer?
SummaryThe treatment paradigm for locally advanced rectal cancer has changed in recent years. Neoadjuvant radiochemotherapy followed by total mesorectal excision and postoperative chemotherapy has been the standard of care since many years. With this multidisciplinary approach the local recurrence rate is low, but the occurrence of distant metastases and impairments of quality of life due to bowel, bladder, and sexual dysfunction are still unresolved problems. The integration of induction or consolidation chemotherapy into the neoadjuvant setting, a  watch-and-wait strategy without surgery for patients with clinical compl...
Source: Memo - Magazine of European Medical Oncology - December 28, 2023 Category: Cancer & Oncology Source Type: research

Total neoadjuvant therapy for each local advanced rectal cancer?
SummaryThe treatment paradigm for locally advanced rectal cancer has changed in recent years. Neoadjuvant radiochemotherapy followed by total mesorectal excision and postoperative chemotherapy has been the standard of care since many years. With this multidisciplinary approach the local recurrence rate is low, but the occurrence of distant metastases and impairments of quality of life due to bowel, bladder, and sexual dysfunction are still unresolved problems. The integration of induction or consolidation chemotherapy into the neoadjuvant setting, a  watch-and-wait strategy without surgery for patients with clinical compl...
Source: Memo - Magazine of European Medical Oncology - December 28, 2023 Category: Cancer & Oncology Source Type: research